Compare IRDM & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IRDM | BEAM |
|---|---|---|
| Founded | 2000 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.3B |
| IPO Year | N/A | 2020 |
| Metric | IRDM | BEAM |
|---|---|---|
| Price | $16.51 | $26.06 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 12 |
| Target Price | $27.60 | ★ $48.09 |
| AVG Volume (30 Days) | ★ 2.1M | 1.9M |
| Earning Date | 10-23-2025 | 11-04-2025 |
| Dividend Yield | ★ 3.62% | N/A |
| EPS Growth | ★ 22.73 | N/A |
| EPS | ★ 1.14 | N/A |
| Revenue | ★ $871,710,000.00 | $55,701,000.00 |
| Revenue This Year | $7.64 | N/A |
| Revenue Next Year | $1.70 | $26.52 |
| P/E Ratio | $14.61 | ★ N/A |
| Revenue Growth | ★ 7.30 | N/A |
| 52 Week Low | $15.65 | $13.53 |
| 52 Week High | $34.45 | $35.25 |
| Indicator | IRDM | BEAM |
|---|---|---|
| Relative Strength Index (RSI) | 40.11 | 53.17 |
| Support Level | $17.37 | $25.53 |
| Resistance Level | $19.32 | $27.87 |
| Average True Range (ATR) | 0.74 | 1.67 |
| MACD | -0.05 | -0.03 |
| Stochastic Oscillator | 9.75 | 49.19 |
Iridium Communications Inc is the commercial provider of communications services offering true globalised coverage, connecting people, organizations and assets to and from anywhere, in real time. The company is a provider of mobile voice and data communications services through a constellation of low earth-orbiting satellites. Iridium's solutions are ideally suited for industries such as maritime, aviation, government/military, emergency/humanitarian services, mining, forestry, oil and gas, heavy equipment, transportation, and utilities. Iridium also provides service to subscribers from the U.S. Department of Defense, as well as other civil and government agencies world-wide. The Company operates in one business segment, providing satellite communications services and products.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.